Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 4(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02633046Phase 4Completed

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Role: lead

NCT03126760Phase 4Terminated

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Role: lead

NCT03400852Phase 2Terminated

A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

Role: lead

All 3 trials loaded